ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study.

Cancer Med · 2019 · PMC6797583 · PMID 31486228

Europe PMC DOI

hedged sentence

0.3920

closest p · 7.8× alpha

0.3920

boldest claim

The sentences

did not reach statistical significanceP = .392not close (p > 0.1)

For patients classified as “high‐risk HFS,” there was a trend for app‐recorded HFS severity to be higher during week 1 (0.209 vs 0.118) and week 2 (0.346 vs 0.167) of the app monitoring period, though this did not reach statistical significance ( P = .392, P = .404, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.